Ying‐Bei Chen

12.9k total citations · 2 hit papers
140 papers, 6.0k citations indexed

About

Ying‐Bei Chen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Ying‐Bei Chen has authored 140 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Pulmonary and Respiratory Medicine, 74 papers in Molecular Biology and 47 papers in Cancer Research. Recurrent topics in Ying‐Bei Chen's work include Renal cell carcinoma treatment (75 papers), Renal and related cancers (55 papers) and Cancer Genomics and Diagnostics (37 papers). Ying‐Bei Chen is often cited by papers focused on Renal cell carcinoma treatment (75 papers), Renal and related cancers (55 papers) and Cancer Genomics and Diagnostics (37 papers). Ying‐Bei Chen collaborates with scholars based in United States, Germany and China. Ying‐Bei Chen's co-authors include Victor E. Reuter, Satish K. Tickoo, A. Ari Hakimi, Paul Russo, James J. Hsieh, Martin H. Voss, Samson W. Fine, Hikmat Al‐Ahmadie, Anuradha Gopalan and Robert J. Motzer and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Ying‐Bei Chen

133 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†

2007 559 citations Elisa Wurmbach, Ying‐Bei Chen et al. Hepatology profile →
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

2016 531 citations A. Ari Hakimi, Ed Reznik et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ying‐Bei Chen United States	39	3.9k	3.1k	1.9k	1.0k	798	140	6.0k
Svetlana Pack United States	47	3.1k 0.8×	1.4k 0.4×	1.1k 0.6×	1.5k 1.5×	933 1.2×	130	6.5k
David S. Shames United States	45	3.0k 0.8×	2.4k 0.8×	1.9k 1.0×	2.9k 2.8×	421 0.5×	110	6.1k
De‐Chen Lin United States	35	4.3k 1.1×	2.2k 0.7×	2.7k 1.4×	2.1k 2.1×	734 0.9×	92	6.8k
Jindan Yu United States	49	8.9k 2.3×	2.4k 0.8×	2.8k 1.5×	1.6k 1.5×	362 0.5×	87	12.7k
Anthony N. Karnezis United States	41	4.2k 1.1×	750 0.2×	1.5k 0.8×	2.4k 2.3×	589 0.7×	90	7.9k
Naotsugu Haraguchi Japan	37	2.9k 0.8×	625 0.2×	1.7k 0.9×	2.5k 2.4×	920 1.2×	168	5.5k
Jianming Ying China	43	2.7k 0.7×	2.1k 0.7×	1.3k 0.7×	2.6k 2.6×	843 1.1×	283	6.1k
Marcella Mottolese Italy	45	3.5k 0.9×	916 0.3×	1.5k 0.8×	3.1k 3.0×	532 0.7×	224	7.2k
Arnab Chakravarti United States	45	3.2k 0.8×	1.1k 0.3×	2.1k 1.1×	1.3k 1.3×	750 0.9×	173	6.1k
Jiejie Xu China	41	2.7k 0.7×	1.5k 0.5×	1.2k 0.7×	2.4k 2.3×	815 1.0×	239	6.1k

Countries citing papers authored by Ying‐Bei Chen

Since Specialization

Citations

This map shows the geographic impact of Ying‐Bei Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying‐Bei Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying‐Bei Chen more than expected).

Fields of papers citing papers by Ying‐Bei Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying‐Bei Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying‐Bei Chen. The network helps show where Ying‐Bei Chen may publish in the future.

Co-authorship network of co-authors of Ying‐Bei Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Ying‐Bei Chen. A scholar is included among the top collaborators of Ying‐Bei Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying‐Bei Chen. Ying‐Bei Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Nailin, et al.. (2025). Biomedical engineering targeting cancer stem cells to reinforce cancer therapy. Coordination Chemistry Reviews. 530. 216494–216494. 9 indexed citations

Khandwala, Yash S., Stephen W. Reese, Andrea Knežević, et al.. (2025). Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma. European Urology Oncology. 9(1). 101–110.

Fitzgerald, Kelly N., Chung‐Han Lee, Martin H. Voss, et al.. (2024). Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. European Urology. 86(2). 90–94. 15 indexed citations

Gebrael, Georges, Hao Wang, Michael A. Carducci, et al.. (2023). 2023 Kidney Cancer Research Summit Abstracts. The Oncologist. 28(Supplement_1). S1–S1. 1 indexed citations

Lee, Chung‐Han, Martin H. Voss, Maria I. Carlo, et al.. (2022). Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology. 40(21). 2333–2341. 105 indexed citations

Tang, Cerise, Mark Zucker, Kelly N. Fitzgerald, et al.. (2022). Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus. 8(5). 1278–1288. 17 indexed citations

Feldman, Darren R., Yasser Ged, Chung‐Han Lee, et al.. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126(24). 5247–5255. 27 indexed citations

Gupta, Sounak, Chad Vanderbilt, Wassim Abida, et al.. (2020). Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 23(3). 507–516. 10 indexed citations

Hakimi, A. Ari, Martin H. Voss, Fengshen Kuo, et al.. (2019). Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery. 9(4). 510–525. 156 indexed citations

10.

Carlo, Maria I., A. Ari Hakimi, Grant D. Stewart, et al.. (2019). Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology. 76(6). 754–764. 76 indexed citations

11.

Hakimi, A. Ari, Ed Reznik, Chung‐Han Lee, et al.. (2016). An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 29(1). 104–116. 531 indexed citations breakdown →

12.

Jiang, Li, et al.. (2015). Evaluation of clinical outcomes of patients with post-stroke wrist and finger spasticity after ultrasonography-guided BTX-A injection and rehabilitation training. Frontiers in Human Neuroscience. 9. 485–485. 9 indexed citations

13.

Voss, Martin H., A. Ari Hakimi, Can G. Pham, et al.. (2014). Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research. 20(7). 1955–1964. 156 indexed citations

14.

Hakimi, A. Ari, Irina Ostrovnaya, Boris Reva, et al.. (2013). Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network. Clinical Cancer Research. 19(12). 3259–3267. 267 indexed citations

15.

Ofengeim, Dimitry, Ying‐Bei Chen, Takahiro Miyawaki, et al.. (2012). N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death. Nature Neuroscience. 15(4). 574–580. 60 indexed citations

16.

Hakimi, A. Ari, Ying‐Bei Chen, James Wren, et al.. (2012). Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. European Urology. 63(5). 848–854. 174 indexed citations

17.

Berman, Sarah, Ying‐Bei Chen, Bing Qi, et al.. (2009). Bcl-xL increases mitochondrial fission, fusion, and biomass in neurons. The Journal of Cell Biology. 184(5). 707–719. 175 indexed citations

18.

Wurmbach, Elisa, Ying‐Bei Chen, Greg Khitrov, et al.. (2007). Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†. Hepatology. 45(4). 938–947. 559 indexed citations breakdown →

19.

Lemmer, Eric R., Ying‐Bei Chen, Steven Yea, et al.. (2006). Dysregulation of hedgehog pathway signaling in hepatocellular carcinoma. Cancer Research. 66. 630–630.

20.

Irusta, Pablo M., Ying‐Bei Chen, & J. Marie Hardwick. (2003). Viral modulators of cell death provide new links to old pathways. Current Opinion in Cell Biology. 15(6). 700–705. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact